Corporate Clients

Realise potential, meet goals, and build value.

Results works as a trusted adviser to corporate clients, including some of the world’s leading pharmaceutical companies. Our clients know they can count on our track-record, depth of experience, professionalism and exceptional technical capabilities.

We work closely with corporate clients that need sector specialist advisors for their buy-side or sell-side M&A needs. Our solutions include strategic reviews of business or facility portfolios, support for acquisitions and divestments, as well as advising on licensing transactions for marketed products.

Commitment to client service is a hallmark of our project teams.

Our disciplined approach and strong technical capability allow our corporate clients to execute projects with confidence and achieve their strategic goals.

We pride ourselves on our integrity and straight talking, giving the best advice to our clients. We are focused on getting the best outcome: we think this demands an adviser who will be clear and considered however complex or pressurised the situation.

David Sanders

Managing Director

Services

We’ve been providing independent M&A and corporate finance advice and execution services to entrepreneurs, corporates and investors in the technology and healthcare sectors for over 30 years. Whether your aim is to realise value or to find a partner for future growth, we will be your guide.

M&A

When the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business.

Divestments

With a strong track record in company carve-outs, we can help you realign your portfolio and redeploy capital to the growth of your core business.

Licensing

We support clients with in-licensing, out-licensing, drug licensing, and facility licensing and we understand the complexities that are unique to licensing deals.

Equity Fundraising

We understand that optimising terms is critical, but so is finding the right partner for growth. We help articulate your equity story, target the best investors and negotiate the right deal.

Strategic Advice

Having completed over 300 transactions, we bring the breadth of perspectives and depth of business experience to provide advice on strategic options for businesses.

Recent Deals

Oct 2021
has been acquired by
Aug 2021
has merged with
a Vespa Capital-backed company
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Monterro-backed company
has acquired
Jul 2021
has received investment from
Jun 2021
has been acquired by
May 2021
has been acquired by
a Behrman Capital-backed company
May 2021
has formed a strategic alliance with

Results. Great people creating great outcomes, together.

Latest Insights

Reports
19th October 2021

The Technology Services Perspective – Q3 2021

Deal activity this quarter continues to be driven by strong confidence in acquiring capability in next-gen, modernisation and cloud-first tech stacks, and premium services. Equally, capturing the end-to-end digital transformation value chain continues to be a key M&A theme to become the strategic operator and engineering partner of choice for large-scale budgets. Public tech companies […]

Reports
19th October 2021

The CyberScope – Q3 2021

Following the COVID-19 pandemic, we continue to see more companies using applications deployed on the cloud and an increasing need for cloud security and zero-trust network access solutions. Expansion of attack surfaces, sophisticated ransomware attacks and publicised security incidents continue to accelerate demand for next-gen security and proactive risk management. Q3 2021 finished strongly with […]

Reports
19th October 2021

The Enterprise Stack – Q3 2021

Following a strong Q2, the path to recovery from the global pandemic is increasingly clear on account of re-opening economies, record-breaking stock markets and an abundant supply of cheap capital fueling investor appetite. Deal making surged in Q3 with volumes up more than 20% on Q2 2021. The quarter witnessed c.500 transactions to further accelerate […]